{"url_path":"/sec/crdf/8-k/2026-06-11/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-11","source_url":"https://www.sec.gov/Archives/edgar/data/1213037/0001193125-26-267563-index.html","accession_number":"0001193125-26-267563","cik":"0001213037","ticker":"CRDF","issuer_name":"Cardiff Oncology, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1213037/0001193125-26-267563-index.html","primary_entity_key":"0001213037","primary_entity_name":"Cardiff Oncology, Inc."},"word_count":381,"has_tables":true,"body_markdown":"Item 5.07 Submission of Matters to a Vote of Security Holders\n\nOn June 11, 2026, Cardiff Oncology, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). A total of 41,614,848 shares of common stock, constituting a quorum, were represented in person or by valid proxies at the Annual Meeting. The final results for each of the matters submitted to a vote of stockholders at the Annual Meeting, as set forth in the Definitive Proxy Statement, filed with the Securities and Exchange Commission on April 23, 2026 are as follows:\n\nProposal 1. All of the six (6) nominees for director were elected to serve until the 2027 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director’s earlier resignation, removal or death. The result of the votes to elect the six (6) directors was as follows:\n\nDirectors\n\n \n\nFor\n\n \n\n \n\nAgainst\n\n \n\n \n\nAbstain\n\n \n\n \n\nBroker Non Vote\n\n \n\nDr. James O. Armitage\n\n \n\n \n\n18,806,657\n\n \n\n \n\n \n\n0\n\n \n\n \n\n \n\n522,756\n\n \n\n \n\n \n\n22,285,435\n\n \n\nDr. Rodney Markin\n\n \n\n \n\n18,647,050\n\n \n\n \n\n \n\n0\n\n \n\n \n\n \n\n682,361\n\n \n\n \n\n \n\n22,285,437\n\n \n\nMani Mohindru, Ph.D.\n\n \n\n \n\n18,942,979\n\n \n\n \n\n \n\n0\n\n \n\n \n\n \n\n386,435\n\n \n\n \n\n \n\n22,285,434\n\n \n\nGary W. Pace, Ph.D.\n\n \n\n \n\n18,877,743\n\n \n\n \n\n \n\n0\n\n \n\n \n\n \n\n451,668\n\n \n\n \n\n \n\n22,285,437\n\n \n\nRenee P. Tannenbaum, Pharm.D.\n\n \n\n \n\n18,790,068\n\n \n\n \n\n \n\n0\n\n \n\n \n\n \n\n539,345\n\n \n\n \n\n \n\n22,285,435\n\n \n\nLâle White\n\n \n\n \n\n18,710,040\n\n \n\n \n\n \n\n0\n\n \n\n \n\n \n\n619,373\n\n \n\n \n\n \n\n22,285,435\n\n \n\n \n\nProposal 2. The appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for its fiscal year ended December 31, 2026 was ratified and approved by the stockholders by the votes set forth in the table below:\n\nFor\n\n \n\nAgainst\n\n \n\nAbstain\n\n \n\nBroker Non Vote\n\n40,239,508\n\n \n\n1,070,807\n\n \n\n304,529\n\n \n\n4\n\nProposal 3. An amendment to the Company’s 2021 Equity Incentive Plan to increase the number of shares issuable thereunder to 15,150,000 shares was approved by the stockholders by the votes set forth in the table below:\n\nFor\n\n \n\nAgainst\n\n \n\nAbstain\n\n \n\nBroker Non Vote\n\n10,740,460\n\n \n\n8,063,520\n\n \n\n525,431\n\n \n\n22,285,437\n\nProposal 4. The advisory vote on the compensation of the Company’s named executive officers was approved by the stockholders by the votes set forth in the table below:\n\nFor\n\n \n\nAgainst\n\n \n\nAbstain\n\n \n\nBroker Non Vote\n\n17,120,176\n\n \n\n1,772,185\n\n \n\n437,049\n\n \n\n22,285,438\n\n \n\n2\n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nCARDIFF ONCOLOGY, INC.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 11, 2026\n\nBy:\n\n/s/ Mani Mohindru\n\n \n\n \n\n \n\nMani Mohindru\n\nChief Executive Officer\n\n \n\n3"}